These compounds have not been evaluated or approved by Health Canada for human use.
Each component has distinct pharmacokinetic properties, with phentermine having a 20-hour half-life and topiramate extending to 21 hours, supporting twice-daily dosing regimens (Hendricks et al., Obesity, 2014)
The patient simply needs to be enrolled in an eligible Part D plan type
In todays fast-paced world, our bodies are constantly exposed to stressors from environmental toxins and poor sleep to daily stress and natural aging
Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al